TARGET AUDIENCE

This CE program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.

LEARNING OBJECTIVES

• Discuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).
• Include autologous or allogeneic HCT and/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
• Manage potential complications resulting from autologous or allogeneic HCT and/or CAR-T cell therapy.
• Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.

ACCREDITATION

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

CREDIT DESIGNATION STATEMENT:

For Physicians:

Rush University Medical Center designates this Live Activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program.  It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

For more information please visit the official event page.